Urine Aquaporin-2: A Promising Marker of Response to the Arginine Vasopressin Type-2 Antagonist, Tolvaptan in Patients with Congestive Heart Failure

International Journal of Molecular Sciences

Teruhiko Imamura²  Koichiro Kinugawa¹ 

[1] Second Department of Internal Medicine, University of Toyama, Toyama 930-0194, JapanDepartment of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, University of Tokyo, Tokyo 113-8655, Japan;

关键词: heart failure;    congestion;    chronic kidney disease;    hyponatremia;   

DOI  :  10.3390/ijms17010105

来源: mdpi

【 摘 要 】

Aquaporin-2, a member of the aquaporin family, is an arginine vasopressin-regulated water channel expressed in the renal collecting duct, and a promising marker of the concentrating and diluting ability of the kidney. The arginine vasopressin type-2 antagonist, tolvaptan, is a new-generation diuretic; it is especially indicated in patients with decompensated heart failure refractory to conventional diuretics. However, the ideal responders to tolvaptan have not yet been identified, and non-responders experience worse clinical courses despite treatment with tolvaptan. Urine aquaporin-2 has recently been demonstrated as a promising predictor of response to tolvaptan. We here validated aquaporin-2-guided tolvaptan therapy in patients with decompensated heart failure. Long-term efficacy of tolvaptan treatment in the responders defined by aquaporin-2 needs to be validated in the future prospective study.

【 授权许可】

CC BY   
© 2016 by the authors; licensee MDPI, Basel, Switzerland.